ERBB2 and carcinoma: However, in one-to-one comparisons, we found no significant differences in the PIK3CA mutation prevalence between DE carcinomas and any of the other carcinoma groups, including the two HER2-positive carcinoma groups (2+ WA and 3+ carcinomas).